BeiGene, DualityBio to Partner on Differentiated Antibody Drug Conjugate Therapy

Published on: 

Biotech to obtain exclusive option for patients with select tumors.

BeiGene, a biotechnology company, and DualityBio, an antibody drug conjugate (ADC) organization, announced a deal for the biotech to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. Under the terms of the partnership, DualityBio will receive an upfront payment, and will be eligible for a payment upon BeiGene exercising its option, with additional payments based upon the achievement of certain development, regulatory, and commercial milestones, totaling up to $1.3 billion.


“With one of the industry’s leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynamic and growing pipeline in solid tumors,” said Lai Wang, PhD., Global Head of R&D, BeiGene. “Through this strategic partnership with DualityBio, we are well positioned to advance this asset globally alongside our initial internally discovered ADC assets with our end-to-end ADC manufacturing capabilities.”

Reference: BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors. BeiGene. July 10, 2023. Accessed July 11, 2023.